bDMARDs and JAK inhibitors with lower risk of infection compared to baseline therapy.

In clinical practice, older rheumatoid arthritis patients tend to receive treatment with biologics (bDMARDs) less frequently than younger patients, although the use of conventional basic therapeutics is often not appropriate due to comorbidities or insufficient efficacy. In a recent analysis of registry data, biologics and JAK inhibitors did not demonstrate an increased risk of serious infections in the patient population over 70 years of age.